Characterization of human H1N1 influenza virus variants selected in vitro with zanamivir in the presence of sialic acid-containing molecules

Virus Research

Volumn 129, Issue 2, 2007, Pages 241-245

  Giannecchini, Simone ^a   Campitelli, Laura ^b   Bandini, Giacomo ^a   Donatelli, Isabella ^b   Azzi, Alberta ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Human influenza virus susceptibility; Neuraminidase inhibitor; Sialic acid containing molecules; Zanamivir in vitro selection

Indexed keywords

FETUIN; SIALIC ACID DERIVATIVE; SIALIDASE INHIBITOR; ZANAMIVIR;

ANIMAL CELL; ARTICLE; CELL STRAIN; CONTROLLED STUDY; IN VITRO STUDY; INFLUENZA VIRUS A H1N1; NONHUMAN; PRIORITY JOURNAL; VIRUS PLAQUE; VIRUS RESISTANCE; VIRUS STRAIN;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; MUTATION; NEURAMINIDASE; OSELTAMIVIR; PLAQUE ASSAY; SIALIC ACIDS; VIRUS REPLICATION; ZANAMIVIR;

HUMAN INFLUENZA VIRUS; ORTHOMYXOVIRIDAE;

EID: 35348821830     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2007.07.010     Document Type: Article

References (23)

1. Abed Y., Goyette N., and Boivin G. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir. Ther. 9 (2004) 577-581
2. Bucher D., and Palese P. The biologically active proteins of influenza virus: neuraminidase. In: Kilbourne E.D. (Ed). The Influenza Viruses and Influenza (1975), Academic Press, New York, NY 83-123
3. Colman P.M., Hoyne P.A., and Lawrence M.C. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J. Virol. 67 (1993) 2972-2980
4. Gambaryan A.S., and Matrosovich M.N. A solid-phase enzyme-linked assay for influenza virus receptor-binding activity. J. Virol. Methods 39 (1992) 111-123
5. Gubareva L.V. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 103 (2004) 199-203
6. Gubareva L.V., Matrosovich M.N., Brenner M.K., Bethell R.C., and Webster R.G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178 (1998) 1257-1262
7. Gubareva L.V., Kaiser L., Matrosovich M.N., Soo-Hoo Y., and Hayden F.G. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183 (2001) 523-531
8. Ives J.A., Carr J.A., Mendel D.B., Tai C.Y., Lambkin R., Kelly L., Oxford J.S., Hayden F.G., and Roberts N.A. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 55 (2002) 307-317
9. Matrosovich M., and Klenk H.-D. Natural and synthetic sialic acid-containing inhibitors of influenza virus receptor binding. Rev. Med. Virol. 13 (2003) 85-97
10. Matrosovich M.N., Matrosovich T.Y., Gray T., Roberts N.A., and Klenk H.D. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol. 78 (2004) 12665-12667
11. McKimm-Breschkin J.L., Sahasrabudhe A., Blick T.J., McDonald M., Colman P.M., Hart G.J., Bethell R.C., and Varghese J.N. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J. Virol. 72 (1998) 2456-2462
12. McKimm-Breschkin J.L., Trivedi T., Hampson A., Hay A., Klimov A., Tashiro M., Hayden F., and Zambon M. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47 (2003) 2264-2272
13. Monto A.S., McKimm-Breschkin J.L., Macken C., Hampson A.W., Hay A., Klimov A., Tashiro M., Webster R.G., Aymard M., Hayden F.G., and Zambon M. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50 (2006) 2395-2402
14. Potier M., Mameli L., Belisle M., Dallaire L., and Melancon S.B. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-d-N-acetylneuraminate) substrate. Anal. Biochem. 94 (1979) 287-296
15. Russell R.J., Haire L.F., Stevens D.J., Collins P.J., Lin Y.P., Blackburn G.M., Hay A.J., Gamblin S.J., and Skehel J.J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443 (2006) 45-49
16. Stevens J., Blixt O., Tumpey T.M., Taubenberger J.K., Paulson J.C., and Wilson I.A. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 312 (2006) 404-410
17. Suzuki Y. Sialobiology of influenza: molecular mechanism of host range variation of influenza viruses. Biol. Pharm. Bull. 28 (2005) 399-408
18. Wang M.Z., Tai C.Y., and Mendel D.B. Mechanism by which mutations at his274 alter sensitivity of influenza a virus N1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob. Agents Chemother. 46 (2002) 3809-3816
19. Wetherall N.T., Trivedi T., Zeller J., Hodges-Savola C., McKimm-Breschkin J.L., Zambon M., and Hayden F.G. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J. Clin. Microbiol. 41 (2003) 742-750
20. Whitley R.J., Hayden F.G., Reisinger K.S., Young N., Dutkowski R., Ipe D., Mills R.G., and Ward P. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20 (2001) 127-133
21. Wilson I.A., Skehel J.J., and Wiley D.C. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution. Nature 289 (1981) 366-373
22. Yen H.L., Herlocher L.M., Hoffmann E., Matrosovich M.N., Monto A.S., Webster R.G., and Govorkova E.A. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 49 (2005) 4075-4084
23. Yen H.L., Hoffmann E., Taylor G., Scholtissek C., Monto A.S., Webster R.G., and Govorkova E.A. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J. Virol. 80 (2006) 8787-8795